CAS NO: | 1175017-90-9 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
生物活性 | AKN-028, a noveltyrosine kinase (TK)inhibitor, is a potent, orally activeFMS-like receptor tyrosine kinase 3 (FLT3)inhibitor with anIC50value of 6 nM. AKN-028 inhibitsFLT3autophosphorylation. AKN-028 induces dose-dependent cytotoxic response (meanIC50=1 μM). AKN-028 inducesapoptosisby activation ofcaspase 3. AKN-028 can be used in research of acute myeloid leukemia (AML)[1]. | ||||||||||||||||
IC50& Target | IC50: 6 nM (FLT3), 140 nM (CLK1), 220 nM (RPS6KA), 520 nM (VEGFR2), and 120 nM (FGFR2)[1] | ||||||||||||||||
体外研究 (In Vitro) | AKN-028 (0.1 nM-100 μM; 15 h; mouse embryonal fibroblasts and human acute megakaryoblastic leukemia M07 cells) inhibits FLT3 and KIT autophosphorylation in a dose-dependent manner[1]. Western Blot Analysis[1]
Cell Cytotoxicity Assay[1]
| ||||||||||||||||
体内研究 (In Vivo) | AKN-028 (15 mg/kg; i.h.; twice daily, for 6 days; male C57 black mice with MV4-11 xenografts) inhibits growth of primary AML and MV4-11 cells in mice[1].
| ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 302.33 | ||||||||||||||||
Formula | C17H14N6 | ||||||||||||||||
CAS 号 | 1175017-90-9 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 125 mg/mL(413.46 mM;Need ultrasonic) 配制储备液
|